Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Inclusion Criteria:

* Histologically confirmed intracranial glioblastoma multiforme (GBM) or gliosarcoma.
* Prior histologic diagnosis of low-grade glioma allowed provided it has been upgraded to GBM after repeat resection
* Has undergone surgery to collect tumor tissue 3-6 weeks ago
* Measurable or assessable disease is not required
* Karnofsky performance status 60-100%
* Life expectancy \> 8 weeks
* White Blood Cell (WBC) ≥ 3,000/mm³
* Absolute Neutrophil Count (ANC) ≥ 1,500/mm³
* Platelet count ≥ 100,000/mm³
* Hemoglobin ≥ 10 g/dL (transfusion allowed)
* Serum Glutamate Oxaloacetate Transaminase (SGOT) \< 2.5 times upper limit of normal (ULN)
* Bilirubin \< 2.5 times ULN
* INR (international normalized ratio) ≤ 1.5 times ULN (except if on therapeutic anticoagulation therapy)
* aPTT (activated partial thromboplastin time) ≤ 1.5 times ULN (except if on therapeutic anticoagulation therapy)
* Creatinine \< 1.5 mg/dL
* Urine protein:creatinine ratio \< 1.0
* Negative pregnancy test
* Fertile patients must use effective contraception
* More than 28 days since prior major surgical procedures or open biopsy (other than craniotomy)
* More than 7 days since prior minor surgical procedures (e.g., placement of PortoCath (port-a-cath - a port placed under the subjects skin), stereotactic biopsy, fine-needle aspirations, or core biopsies)
* More than 4 weeks since prior and no concurrent participation in another experimental drug study.
* Prior or concurrent corticosteroids, anti-epileptic drugs, analgesics, or other drugs to treat symptoms or prevent complications are allowed
* Concurrent full-dose warfarin or its equivalent (i.e., unfractionated and/or low molecular weight heparin) allowed

Exclusion Criteria:

* unstable angina
* BP \> 150/100 mm Hg
* New York Heart Association (NYHA) class II-IV congestive heart failure
* myocardial infarction within the past 6 months
* stroke within the past 6 months
* clinically significant peripheral vascular disease
* evidence of bleeding diathesis or coagulopathy
* intracerebral abscess within past 6 months
* abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
* serious, non-healing wound, ulcer, or bone fracture
* Any wound requiring surgical intervention (including scalp wounds requiring cranioplasty) allowed provided the wound is clean and without further infection post-surgical intervention
* significant traumatic injury within the past 28 days
* concurrent serious uncontrolled medical illness including, but not limited to, the following:
* Ongoing or active infection requiring IV antibiotics
* Psychiatric illness/social situation that would limit compliance with study requirements
* Disorders associated with significant immunocompromised state (e.g., HIV, systemic lupus erythematosus)
* other cancer within the past 3 years, except nonmelanoma skin cancer or carcinoma in situ of the cervix
* disease that would obscure toxicity or dangerously alter drug metabolism
* significant medical illness that, in the investigator's opinion, cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate study therapy
* prior radiotherapy to the brain
* prior cytotoxic or non-cytotoxic drug therapy or experimental drug therapy for the brain tumor
* prior Gliadel wafers
* concurrent participation in any other clinical trial
* concurrent GM-CSF (granulocyte-macrophage colony-stimulating factor)
* concurrent stereotactic radiosurgery or brachytherapy
* concurrent major surgical procedure
* other concurrent anticancer therapy, including chemotherapy, hormonal therapy, radiotherapy, or immunotherapy